Abstract:Objective: During Toll-like receptor 4 signaling, the Toll/interleukin-1 receptor domain is essential for interactions with downstream Toll/interleukin-1 receptor domain-containing adaptor proteins. The aim of this study is to investigate the role of the Toll/interleukin-1 receptor domain in the Toll-like receptor 4 signaling pathway during hepatic ischemia and reperfusion injury.Design: We genetically blocked the function of Toll/interleukin-1 receptor domain in mice and examined the effect on Toll-like receptor 4 signaling and the response to hepatic ischemia and reperfusion.Setting: University research laboratory.Subjects: Male BALB/c mice.Interventions: Male BALB/c mice were hydrodynamically administrated the target gene plasmid pTIR-IRES2-EGFP, empty vector containing enhanced green fluorescent protein, or normal saline. Animals underwent 90 minutes of partial hepatic ischemia, followed by 6 or 24 hours of reperfusion. Hepatic injury was assessed by measuring serum alanine transaminase, hepatic histology, and malondialdehyde. The expression of inflammatory cytokines and nuclear factor-B phosphorylation was examined in liver tissues. Hepatic apoptosis was evaluated by caspase-3 assays, terminal deoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nick-end labeling staining, and the activation of Jun N-terminal kinase and p38 mitogen-activated protein kinase.Measurements and Main Results: Blocking the Toll/interleukin-1 receptor domain resulted in markedly lower serum alanine transaminase levels, reduced histologic injury, and lower malondialdehyde levels following 6 or 24 hours of hepatic reperfusion than mice receiving the vector alone or normal saline. Anti-Toll/interleukin-1 receptor treatment also reduced Toll-like receptor 4 expression and disrupted Toll/interleukin-1 receptor-Toll/interleukin-1 receptor interactions in Toll-like receptor 4 signaling pathways. Blocking the Toll/interleukin-1 receptor domain also prevented Toll-like receptor 4-mediated mitogen-activated protein kinase activation (via Jun N-terminal kinase and p38 mitogen-activated protein kinase), an activation that mediated liver ischemia and reperfusion injury via caspase-3 activation, resulting in increased hepatocellular apoptosis. Lastly, blocking the Toll/interleukin-1 receptor domain decreased inflammatory cytokine production by inhibiting nuclear factor-B activation.Conclusions: Toll/interleukin-1 receptor domain inhibition disrupts the interaction of Toll-like receptor 4 with its adaptor proteins, which abrogates downstream signaling pathways and prevents the activation of nuclear factor-B and Jun N-terminal kinase/p38. This reduction in signaling consequently reduces hepatic inflammation, cell apoptosis, and hepatic damage. Toll/interleukin-1 receptor domain-targeted therapy thus represents a new approach to inhibit the intracellular Toll-like receptor 4 signaling pathway and reveals novel therapeutic target sites, which will facilitate the development of specific therapeutic agents.

Integrated Omics Reveals Tollip As an Regulator and Therapeutic Target for Hepatic Ischemia‐Reperfusion Injury in Mice

Inhibiting the Toll-Like Receptor 4 Toll/interleukin-1 Receptor Domain Protects Against Hepatic Warm Ischemia and Reperfusion Injury in Mice.

Tollip is a critical mediator of cerebral ischaemia–reperfusion injury

TRPM2 Mediates Hepatic Ischemia–Reperfusion Injury via Ca <sup>2+</sup> -Induced Mitochondrial Lipid Peroxidation through Increasing ALOX12 Expression

T-Cell Immunoglobulin and Mucin Domain 4 (Tim-4) Signaling in Innate Immune-Mediated Liver Ischemia-Reperfusion Injury (Iri)

Toll-like Receptor 4 Involvement in Hepatic Ischemia/reperfusion Injury in Mice

TNIP1 Alleviates Hepatic Ischemia/reperfusion Injury Via the TLR2-Myd88 Pathway.

A Role of Microrna‐370 in Hepatic Ischaemia‐reperfusion Injury by Targeting Transforming Growth Factor‐β Receptor II

Targeting the Hepatic Microenvironment to Improve Ischemia/Reperfusion Injury: New Insights into the Immune and Metabolic Compartments

Targeting TRAF3 Signaling Protects Against Hepatic Ischemia/reperfusions Injury

Spatial transcriptomics analysis of zone-dependent hepatic ischemia-reperfusion injury murine model

TWEAK is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/ Reperfusion Injury

Endogenous Danger Signals Trigger Hepatic Ischemia/Reperfusion Injury Through Toll-Like Receptor 4/nuclear Factor-Kappa B Pathway

TNFAIP3 Interacting Protein 3 Is an Activator of Hippo‐YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury

Comprehensive and Combined Omics Analysis Reveals Factors of Ischemia-Reperfusion Injury in Liver Transplantation

TXNIP Knockdown Alleviates Hepatocyte Ischemia Reperfusion Injury Through Preventing P38/jnk Pathway Activation

Novel Targets and Therapeutic Strategies to Protect Against Hepatic Ischemia Reperfusion Injury

Tripartite Motif‐Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β–Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation

Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice.

Signaling through hepatocyte vasopressin receptor 1 protects mouse liver from ischemia-reperfusion injury.